Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today is providing a number of strategic updates, including its recently executed option agreement with Incyte ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback